Everyone Wrote Off Mamaearth After the IPO. Honasa Just Proved Them All Wrong — With a Dividend to Rub It In

Two years ago, Honasa Consumer was the Indian D2C company everyone loved to worry about. Revenue was plateauing. The stock had fallen sharply from its IPO price. Analysts were questioning whether Mamaearth's toxin-free brand equity could translate into durable pricing power. The offline distribution push was expensive and uncertain.

Fast forward to May 2026, and the same company has just reported its best year in history, declared its first-ever dividend, acquired a men's grooming brand that crossed ₹100 crore ARR in its very first quarter of consolidation, and set itself a target of improving EBITDA margins by 100 basis points every single year going forward.

The turnaround is real. And the strategic clarity behind it is considerably sharper than it was at the time of listing.

THE NUMBERS: FY26 WAS THE YEAR EVERYTHING CLICKED

For the full year FY26, Honasa Consumer's operating revenue reached ₹2,479 crore — up 20% year-on-year. Annual net profit rose 175% to ₹200 crore. EBITDA tripled to ₹231 crore. Volume growth came in at 23% for the year, and the company generated ₹134 crore in free cash flow.

The Q4 print was even stronger. Highest-ever quarterly revenue of ₹682 crore on a like-for-like basis — growing 28% year-on-year. EBITDA surged 186% to ₹77 crore, with margins improving to approximately 11%. Net profit rose 178% to ₹69 crore. This was the third consecutive quarter of 20%+ growth.

The working capital cycle turned negative at minus 14 days in Q4 — a sign that scale is translating into better operating rhythm and that the business is no longer consuming cash to fund its own growth.

The board declared a maiden final dividend of ₹3 per equity share — representing 51.2% of FY26 standalone profit after tax. For a company that was posting losses just three years ago, declaring a dividend that pays out half its standalone profits is a statement of confidence — in the cash generation, in the balance sheet, and in the sustainability of the earnings trajectory.

THE MAMAEARTH BRAND: BACK TO DOUBLE-DIGIT GROWTH

Mamaearth — the flagship brand that built the company's reputation on toxin-free, natural formulations for babies, mothers, and eventually everyone — had a difficult FY25 as it navigated an offline distribution reset. Mamaearth returned to double-digit growth during FY26 — a recovery that was not guaranteed when the restructuring began.

The offline distribution expansion was a critical driver. Approximately 1.2 lakh retail outlets were directly billed through distributors in FY26 — building the physical retail presence that a brand reaching for mainstream Indian consumer durability cannot avoid. The shift from being primarily a digital-first brand to having genuine offline breadth is the single most important strategic achievement of the past eighteen months. Digital-only brands hit a ceiling; brands with both digital and physical reach compound.

The brand's positioning — centred on "goodness inside" and ingredient transparency — continues to resonate in a market where consumers are increasingly scrutinising product labels and demanding cleaner formulations. In the beauty and personal care segment, that positioning is a genuine long-term moat rather than a passing trend.

THE DERMA CO: THE BRAND THAT IS BECOMING THE GROWTH ENGINE

If Mamaearth is the legacy brand, The Derma Co is the future. The Derma Co continues to deliver strong growth across channels, maintaining a double-digit EBITDA profile.

The brand occupies a specific and defensible space in India's skincare market: dermatologist-inspired formulations at accessible price points, targeting the skincare-aware consumer who knows what niacinamide and salicylic acid do but cannot afford a clinical brand. It is the segment where the Indian middle class is most actively trading up — and The Derma Co is perfectly positioned within it.

Management has explicitly stated that The Derma Co is their biggest long-term bet — the brand they believe can become a significant standalone business rather than simply a portfolio addition. The 100 basis point annual EBITDA improvement target for the overall company is partly predicated on The Derma Co's mix contribution growing as a share of total revenue — since skincare products carry structurally better margins than haircare or baby care.

REGINALD MEN: THE SURPRISE OF FY26

The acquisition and consolidation of Reginald Men — a men's grooming brand — was initially met with questions about capital allocation. Those questions have been answered by performance.

Reginald Men, in its first quarter of consolidation, achieved an Annual Recurring Revenue of over ₹100 crore — doubling its revenue year-on-year.

The men's grooming market in India is one of the most underpenetrated segments in beauty and personal care — historically served by a handful of legacy brands that have barely evolved their positioning in decades. The same consumer who is buying The Derma Co's niacinamide serum for himself is looking for a men's grooming brand that understands modern skincare, uses decent ingredients, and does not cost a fortune. Reginald Men is Honasa's answer to that need.

Management has confirmed plans to scale Reginald Men as a broader men's grooming platform — extending beyond its current product range into a full portfolio play covering face care, haircare, and body care for men. The ₹100 crore ARR in the first quarter of consolidation suggests the demand is genuine, not manufactured.

THE 100 BPS ANNUAL EBITDA TARGET: AMBITIOUS BUT CREDIBLE

The most specific and consequential forward guidance Honasa's management has issued is the 100 basis point annual improvement in EBITDA margins — targeting a sustained march from the current 11% level toward 15-16% over the medium term.

The levers are clear. A higher contribution from The Derma Co and Reginald Men — both of which carry better margin profiles than Mamaearth's core portfolio — will naturally improve the blended margin mix. Offline distribution efficiency improves as the network matures and fill rates improve. Marketing spend as a percentage of revenue tends to decline as brand awareness compounds. And the working capital improvement already underway reduces the hidden cost of financing the business's own growth cycle.

Whether the 100 basis point improvement materialises year after year depends on execution rather than ambition. But the underlying drivers are all moving in the right direction simultaneously.

THE VALUATION: PREMIUM THAT STILL REQUIRES PROOF

Honasa Consumer has a total market capitalisation of ₹11,768 crore as of May 21, 2026. At approximately 59x trailing earnings — against an FY26 PAT of ₹200 crore — the stock is priced for continued strong growth and margin expansion.

That multiple is demanding but not irrational given the trajectory. A company that tripled its EBITDA in a single year, returned to double-digit revenue growth after a difficult restructuring period, declared its first dividend, and simultaneously acquired a brand growing at 100%+ deserves a premium over the sector average.

The risk is equally clear: if the 100 basis point margin improvement timeline slips, or if Mamaearth's offline distribution costs prove harder to leverage than expected, the earnings growth that justifies the current multiple will disappoint. The Derma Co needs to continue delivering double-digit EBITDA margins at scale — not just at current revenue levels — to support the long-term margin thesis.

For investors, FY27 is the year where the thesis gets tested properly. FY26 was the recovery year. FY27 is where the proof of durability begins.